Syner-G BioPharma Group
Ron Kraus has extensive work experience in the biopharmaceutical industry. Ron is currently the Chief Executive Officer at Syner-G BioPharma Group starting in June 2022. Prior to that, they served as the Chief Operating Officer at Cytel from March 2020 to June 2022. Ron has a long history with Parexel, where they held various leadership positions. Ron was the Corporate Vice President - Global Project Leadership from July 2016 to March 2020 and the Corporate Vice President & Worldwide Head of PAREXEL Consulting from February 1995 to June 2016.
Ron Kraus earned a Bachelor's degree in Mechanical Engineering from the University of Massachusetts Amherst, graduating in 1994 after completing their studies from 1990 to 1994.
Syner-G BioPharma Group
Syner-G BioPharma Group provides in-depth expertise across the three key elements of Chemistry, Manufacturing, and Controls (CMC): Regulatory Services, Technical Development, and Quality/IT. We call this CMC 360™. We also provide medical writing services, with expertise in authoring a variety of regulatory documents across a wide range of therapeutic areas and in all phases of development. Our regulatory affairs services include the development and implementation of global regulatory strategic plans, regulatory agency meeting support, and electronic submissions to regulatory authorities around the world. We have the skill set and experience to guide your prime asset through any development challenges and along the ever-changing maze of regulatory filing pathways, to a position of full compliance, and high quality. Our expertise spans small molecules, peptides, oligonucleotides, biologics, monoclonal antibodies, antibody-drug conjugates, and cell and gene therapy products.